AU2012300844A1 - Substituted annellated pyrimidine and the use thereof - Google Patents
Substituted annellated pyrimidine and the use thereofInfo
- Publication number
- AU2012300844A1 AU2012300844A1 AU2012300844A AU2012300844A AU2012300844A1 AU 2012300844 A1 AU2012300844 A1 AU 2012300844A1 AU 2012300844 A AU2012300844 A AU 2012300844A AU 2012300844 A AU2012300844 A AU 2012300844A AU 2012300844 A1 AU2012300844 A1 AU 2012300844A1
- Authority
- AU
- Australia
- Prior art keywords
- pyrimidine
- annellated
- substituted
- substituted annellated
- annellated pyrimidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102011082041.8 | 2011-09-02 | ||
DE201110082041 DE102011082041A1 (en) | 2011-09-02 | 2011-09-02 | New substituted fused pyrimidine compounds are guanylate cyclase stimulators useful to treat and/or prevent e.g. heart failure, hypertension, ischemia, vascular disease, renal failure, thromboembolic disorders and fibrotic diseases |
DE102012200351.7 | 2012-01-11 | ||
DE201210200351 DE102012200351A1 (en) | 2012-01-11 | 2012-01-11 | New substituted annellated pyrimidine compounds are guanylate cyclase stimulators useful to treat and/or prevent heart failure, hypertension, ischemia, vascular disease, renal failure, thromboembolic disorders and fibrotic diseases |
PCT/EP2012/066876 WO2013030288A1 (en) | 2011-09-02 | 2012-08-30 | Substituted annellated pyrimidine and the use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2012300844A1 true AU2012300844A1 (en) | 2014-03-13 |
AU2012300844B2 AU2012300844B2 (en) | 2017-03-30 |
Family
ID=47755368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2012300844A Ceased AU2012300844B2 (en) | 2011-09-02 | 2012-08-30 | Substituted annellated pyrimidine and the use thereof |
Country Status (27)
Country | Link |
---|---|
US (2) | US8859569B2 (en) |
EP (1) | EP2751106B1 (en) |
JP (1) | JP6054967B2 (en) |
KR (1) | KR20140068112A (en) |
CN (1) | CN104039784B (en) |
AP (1) | AP2014007541A0 (en) |
AR (1) | AR087769A1 (en) |
AU (1) | AU2012300844B2 (en) |
BR (1) | BR112014005110A2 (en) |
CA (1) | CA2847075A1 (en) |
CL (1) | CL2014000504A1 (en) |
CO (1) | CO6950471A2 (en) |
CR (1) | CR20140096A (en) |
CU (1) | CU20140025A7 (en) |
DO (1) | DOP2014000043A (en) |
EA (1) | EA026701B1 (en) |
EC (1) | ECSP14013224A (en) |
GT (1) | GT201400033A (en) |
HK (1) | HK1198698A1 (en) |
IL (1) | IL231244A (en) |
MA (1) | MA35365B1 (en) |
MX (1) | MX348470B (en) |
PE (1) | PE20141582A1 (en) |
SG (1) | SG11201400083VA (en) |
TW (1) | TWI565708B (en) |
UY (1) | UY34306A (en) |
WO (1) | WO2013030288A1 (en) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3002298B1 (en) | 2007-11-21 | 2019-08-28 | Oregon Health & Science University | Anti-factor xi monoclonal antibodies and methods of use thereof |
SI2373691T1 (en) | 2008-12-18 | 2019-05-31 | Oregon Health & Science University | Anti-fxi antibodies and methods of use |
DE102010021637A1 (en) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
MX2013000198A (en) | 2010-07-09 | 2013-01-28 | Bayer Ip Gmbh | Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases. |
JP6005134B2 (en) | 2011-04-21 | 2016-10-12 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | Fluoroalkyl-substituted pyrazolopyridines and uses thereof |
PE20190180A1 (en) | 2011-11-25 | 2019-02-01 | Adverio Pharma Gmbh | PROCEDURE FOR THE PREPARATION OF 5-FLUORO-1H-PYRAZOLOPYRIDINES SUBSTITUTED |
CN102491974B (en) * | 2011-12-12 | 2013-08-07 | 南京药石药物研发有限公司 | Method for synthesizing 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-formamidine hydrochloride |
DE102012200352A1 (en) * | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituted, fused imidazoles and pyrazoles and their use |
DE102012200349A1 (en) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituted fused pyrimidines and triazines and their use |
DE102012200360A1 (en) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituted triazines and their use |
WO2013131923A1 (en) * | 2012-03-06 | 2013-09-12 | Bayer Intellectual Property Gmbh | Substituted azabicycles and use thereof |
BR112014027952B1 (en) | 2012-05-10 | 2022-06-21 | Bayer Pharma Aktiengesellschaft | Human monoclonal antibodies capable of binding to clotting factor xi, its use, pharmaceutical composition and drug comprising them, nucleic acid encoding it, as well as vector |
PT2927231T (en) | 2012-11-30 | 2017-10-31 | Astellas Pharma Inc | Imidazopyridine compounds |
AP2015008670A0 (en) | 2013-02-21 | 2015-08-31 | Adverio Pharma Gmbh | Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-B]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate |
JP2016513129A (en) * | 2013-03-01 | 2016-05-12 | バイエル・ファルマ・アクティエンゲゼルシャフト | Benzyl-substituted pyrazolopyridines and uses thereof |
PE20151755A1 (en) * | 2013-03-01 | 2015-12-04 | Bayer Pharma AG | FUSED PYRIMIDINES REPLACED WITH TRIFLUOROMETHYL AND ITS USES |
WO2014195333A1 (en) | 2013-06-04 | 2014-12-11 | Bayer Pharma Aktiengesellschaft | 3-aryl-substituted imidazo[1,2-a]pyridines and the use thereof |
CN105745215A (en) * | 2013-07-10 | 2016-07-06 | 拜耳制药股份公司 | Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof |
EP3092231B1 (en) | 2013-12-11 | 2018-06-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
US9783552B2 (en) | 2013-12-11 | 2017-10-10 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
EP3079701B1 (en) * | 2013-12-11 | 2021-08-11 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
EP3094327A1 (en) | 2014-01-13 | 2016-11-23 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
WO2015124544A1 (en) * | 2014-02-19 | 2015-08-27 | Bayer Pharma Aktiengesellschaft | 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines |
US9796733B2 (en) | 2014-06-04 | 2017-10-24 | Merck Sharp & Dohme Corp. | Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators |
CN107108658A (en) * | 2014-08-29 | 2017-08-29 | 拜耳医药股份有限公司 | Substituted cyclic pyrimidin and application thereof |
CN107074883A (en) * | 2014-08-29 | 2017-08-18 | 拜耳医药股份有限公司 | Cyclic pyrimidin of amino substitution and application thereof |
CA2961489A1 (en) | 2014-09-17 | 2016-03-24 | Glen Robert RENNIE | Sgc stimulators |
US20170333435A1 (en) | 2014-11-06 | 2017-11-23 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
US20180185368A1 (en) | 2014-11-06 | 2018-07-05 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
NZ731897A (en) | 2014-11-06 | 2023-11-24 | Bial – R&D Invest S A | Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders |
TW201625635A (en) | 2014-11-21 | 2016-07-16 | 默沙東藥廠 | Triazolo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
CN107001361A (en) | 2014-12-02 | 2017-08-01 | 拜耳医药股份有限公司 | Imidazo [1,2 a] pyridine of heteroaryl substitution and application thereof |
US10435402B2 (en) | 2015-01-08 | 2019-10-08 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
ES2933674T3 (en) | 2015-03-13 | 2023-02-13 | Univ Indiana Res & Tech Corp | PDE5 inhibitors for use in reducing renal cyst size and/or preventing renal cyst growth |
US20180169095A1 (en) | 2015-05-06 | 2018-06-21 | Bayer Pharma Aktiengesellschaft | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc) |
WO2016191334A1 (en) | 2015-05-27 | 2016-12-01 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
US10213429B2 (en) | 2015-05-28 | 2019-02-26 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
WO2017013010A1 (en) | 2015-07-23 | 2017-01-26 | Bayer Pharma Aktiengesellschaft | Stimulators and/or activators of soluble guanylate cyclase (sgc) in combination with an inhibitor of neutral endopeptidase (nep inhibitor) and/or an angiotensin aii antagonist and the use thereof |
KR20180094965A (en) | 2015-12-14 | 2018-08-24 | 아이언우드 파마슈티컬스, 인코포레이티드 | Use of sGC Stimulants for the Treatment of Gastric Sphincter Dysfunction |
WO2017107052A1 (en) * | 2015-12-22 | 2017-06-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase stimulators |
US10787454B2 (en) | 2016-04-06 | 2020-09-29 | BIAL—BioTech Investments, Inc. | Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
JP7034935B2 (en) | 2016-04-06 | 2022-03-14 | リソソーマル・セラピューティクス・インコーポレイテッド | Pyrrolo [1,2-a] pyrimidinylcarboxamide compounds and their use in the treatment of medical disorders |
KR20180133461A (en) | 2016-04-06 | 2018-12-14 | 리소소말 테라퓨틱스 인크. | Pyrazolo [1,5-a] pyrimidinylcarboxamide compounds and their use in the treatment of medical disorders |
US11345698B2 (en) | 2016-05-05 | 2022-05-31 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders |
US11168087B2 (en) | 2016-05-05 | 2021-11-09 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders |
WO2017197555A1 (en) | 2016-05-16 | 2017-11-23 | Merck Sharp & Dohme Corp. | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators |
US10925876B2 (en) | 2016-05-18 | 2021-02-23 | Merck Sharp & Dohme Corp. | Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders |
JP7237823B2 (en) | 2016-10-11 | 2023-03-13 | バイエル ファーマ アクチエンゲゼルシャフト | Combinations comprising SGC activators and mineralocorticoid receptor antagonists |
US10918639B2 (en) | 2016-10-11 | 2021-02-16 | Bayer Pharma Aktiengesellschaft | Combination containing SGC stimulators and mineralocorticoid receptor antagonists |
CN110267949A (en) | 2016-11-08 | 2019-09-20 | 塞科里昂医疗股份有限公司 | SGC stimulant |
WO2018111795A2 (en) | 2016-12-13 | 2018-06-21 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of esophageal motility disorders |
WO2018130443A1 (en) | 2017-01-10 | 2018-07-19 | Bayer Aktiengesellschaft | Heterocyclene derivatives as pest control agents |
US11242335B2 (en) | 2017-04-11 | 2022-02-08 | Sunshine Lake Pharma Co., Ltd. | Fluorine-substituted indazole compounds and uses thereof |
RU2662308C1 (en) * | 2017-12-25 | 2018-07-25 | Феркат Адельзянович Халиуллин | Agent for treatment and prevention of thrombosis |
MX2020012230A (en) | 2018-05-15 | 2021-01-29 | Bayer Ag | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization. |
US20210177846A1 (en) | 2018-07-11 | 2021-06-17 | Cyclerion Therapeutics, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS |
WO2020164008A1 (en) | 2019-02-13 | 2020-08-20 | Bayer Aktiengesellschaft | Process for the preparation of porous microparticles |
TWI794742B (en) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | Antiviral compounds |
EP3925953A1 (en) * | 2020-06-16 | 2021-12-22 | Adverio Pharma GmbH | Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate |
WO2022221514A1 (en) | 2021-04-16 | 2022-10-20 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
WO2024038398A1 (en) * | 2022-08-18 | 2024-02-22 | Torrent Pharmaceuticals Limited | Novel salt of substituted 5-fluoro-1h-pyrazolopyridines and its uses |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1029653A (en) | 1910-05-11 | 1912-06-18 | Waterbury Farrel Foundry Co | Slotting-machine. |
GB9314412D0 (en) | 1993-07-13 | 1993-08-25 | Rhone Poulenc Agriculture | New compositions of matter |
EP0743066A3 (en) | 1995-05-16 | 1998-09-30 | Mitsui Pharmaceuticals, Inc. | Wound-healing agent |
DE19642255A1 (en) | 1996-10-14 | 1998-04-16 | Bayer Ag | Use of 1-benzyl-3- (substituted-hetaryl) fused pyrazole derivatives |
US6451805B1 (en) | 1997-11-14 | 2002-09-17 | Bayer Aktiengesellschaft | Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases |
DE19834044A1 (en) | 1998-07-29 | 2000-02-03 | Bayer Ag | New substituted pyrazole derivatives |
DE19834047A1 (en) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituted pyrazole derivatives |
DE10021069A1 (en) | 2000-04-28 | 2001-10-31 | Bayer Ag | Substituted pyrazole derivative |
US6903089B1 (en) | 2000-11-22 | 2005-06-07 | Bayer Aktiengesellschaft | Lactam-substituted pyrazolopyridine derivatives |
DE10132416A1 (en) | 2001-07-04 | 2003-01-16 | Bayer Ag | New morpholine-bridged pyrazolopyridine derivatives |
DE10220570A1 (en) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamate-substituted pyrazolopyridines |
DE10232571A1 (en) | 2002-07-18 | 2004-02-05 | Bayer Ag | 4-amino substituted pyrimidine derivatives |
JP4765623B2 (en) | 2003-05-09 | 2011-09-07 | 旭硝子株式会社 | Process for producing 2-chloro-5-fluoro-3-substituted pyridine or a salt thereof |
CN100355732C (en) | 2003-11-03 | 2007-12-19 | 上海药明康德新药开发有限公司 | Preparation of 2-Cl-5-F-nicotinate and nicotonic acid |
RU2008116844A (en) | 2005-09-29 | 2009-11-10 | Мерк энд Ко., Инк. (US) | Acylated Spiropiperidine Derivatives as Modulators of the Melanocortin-4 Receptor |
DE102006043443A1 (en) | 2006-09-15 | 2008-03-27 | Bayer Healthcare Ag | Novel aza-bicyclic compounds and their use |
JP5553751B2 (en) | 2007-07-31 | 2014-07-16 | バーテックス ファーマシューティカルズ インコーポレイテッド | Process for preparing 5-fluoro-1H-pyrazolo [3,4-b] pyridin-3-amine and its derivatives |
JP2011513483A (en) | 2008-03-10 | 2011-04-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | Pyrimidines and pyridines useful as inhibitors of protein kinases |
EP2373317B1 (en) | 2008-11-25 | 2016-12-14 | Merck Sharp & Dohme Corp. | 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases |
WO2011115804A1 (en) | 2010-03-17 | 2011-09-22 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
AU2011258436B2 (en) * | 2010-05-27 | 2014-06-12 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
CA2804471A1 (en) | 2010-07-09 | 2012-01-12 | Bayer Intellectual Property Gmbh | Ring-fused 4 -aminopyrimidines and use thereof as stimulators of soluble guanylate cyclases |
MX2013000198A (en) | 2010-07-09 | 2013-01-28 | Bayer Ip Gmbh | Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases. |
DE102010040233A1 (en) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclic aza heterocycles and their use |
WO2012152629A1 (en) * | 2011-05-06 | 2012-11-15 | Bayer Intellectual Property Gmbh | Substituted imidazopyridines and imidazopyridazines and the use thereof |
JP6005134B2 (en) | 2011-04-21 | 2016-10-12 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | Fluoroalkyl-substituted pyrazolopyridines and uses thereof |
WO2013004785A1 (en) * | 2011-07-06 | 2013-01-10 | Bayer Intellectual Property Gmbh | Heteroaryl-substituted pyrazolopyridines and use thereof as soluble guanylate cyclase stimulators |
-
2012
- 2012-08-30 CA CA 2847075 patent/CA2847075A1/en not_active Abandoned
- 2012-08-30 SG SG11201400083VA patent/SG11201400083VA/en unknown
- 2012-08-30 US US13/599,975 patent/US8859569B2/en not_active Expired - Fee Related
- 2012-08-30 JP JP2014527659A patent/JP6054967B2/en not_active Expired - Fee Related
- 2012-08-30 BR BR112014005110A patent/BR112014005110A2/en active Search and Examination
- 2012-08-30 PE PE2014000263A patent/PE20141582A1/en not_active Application Discontinuation
- 2012-08-30 WO PCT/EP2012/066876 patent/WO2013030288A1/en active Application Filing
- 2012-08-30 AU AU2012300844A patent/AU2012300844B2/en not_active Ceased
- 2012-08-30 EP EP12766292.2A patent/EP2751106B1/en active Active
- 2012-08-30 EA EA201490546A patent/EA026701B1/en not_active IP Right Cessation
- 2012-08-30 CN CN201280053847.5A patent/CN104039784B/en not_active Expired - Fee Related
- 2012-08-30 AP AP2014007541A patent/AP2014007541A0/en unknown
- 2012-08-30 KR KR1020147008313A patent/KR20140068112A/en unknown
- 2012-08-30 MX MX2014002075A patent/MX348470B/en active IP Right Grant
- 2012-08-31 UY UY0001034306A patent/UY34306A/en not_active Application Discontinuation
- 2012-08-31 TW TW101131665A patent/TWI565708B/en not_active IP Right Cessation
- 2012-09-03 AR ARP120103249A patent/AR087769A1/en active Pending
-
2014
- 2014-02-21 CO CO14037097A patent/CO6950471A2/en active IP Right Grant
- 2014-02-26 GT GT201400033A patent/GT201400033A/en unknown
- 2014-02-27 CR CR20140096A patent/CR20140096A/en unknown
- 2014-02-28 MA MA36787A patent/MA35365B1/en unknown
- 2014-02-28 DO DO2014000043A patent/DOP2014000043A/en unknown
- 2014-02-28 EC ECSP14013224 patent/ECSP14013224A/en unknown
- 2014-02-28 CL CL2014000504A patent/CL2014000504A1/en unknown
- 2014-03-02 IL IL231244A patent/IL231244A/en not_active IP Right Cessation
- 2014-03-03 CU CUP2014000025A patent/CU20140025A7/en unknown
- 2014-09-19 US US14/491,558 patent/US20150105374A1/en not_active Abandoned
- 2014-12-04 HK HK14112217.6A patent/HK1198698A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012300844A1 (en) | Substituted annellated pyrimidine and the use thereof | |
HK1198698A1 (en) | Substituted annellated pyrimidine and the use thereof | |
AU2017202203A1 (en) | Wheeled chair | |
IL228322A0 (en) | Dispiropyrrolidine derivatives compositions comprising the same and uses thereof | |
EP2661485A4 (en) | Assay cartridges and methods of using the same | |
EP3083606A4 (en) | Pyrimidines and use thereof | |
GB201111705D0 (en) | Compounds and their use | |
HK1193100A1 (en) | Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament -3--[310]-3-- | |
HK1198646A1 (en) | Substituted imidazopyridines and the use thereof | |
GB201114448D0 (en) | Compounds and their use | |
EP2861118B8 (en) | Sanitary set | |
EP2636234A4 (en) | Configuration uncertainty | |
AU2013100947A4 (en) | Surface Stabliser and Uses Thereof | |
AU2012905085A0 (en) | Complex-formation-modulating agents and uses therefor | |
AU2011900316A0 (en) | Metallocomplexes and their use as antibacterial agents | |
AU2011902647A0 (en) | The STUBBO | |
AU2011902984A0 (en) | Compositions and their use | |
AU2011904672A0 (en) | Therapeutic Compounds and Uses Thereof | |
AU2012901002A0 (en) | Antiviral agents and methods | |
AU2011904936A0 (en) | Bismuth compounds and uses | |
AU2012900986A0 (en) | Compounds and Methods - II | |
AU2012900987A0 (en) | Compounds and Methods - I | |
AU2012903933A0 (en) | Chaz's Knotchamacallit | |
AU2012905401A0 (en) | The Ironstein | |
AU2012903508A0 (en) | Breast-protective orthosis and use thereof |